Forget SpaceX Stock -- Is RocketLab the Better Buy?

SpaceX is reportedly preparing for a potential IPO later this year with a target valuation of $1.75 trillion and as much as 30% of shares potentially allocated to retail investors. The article argues the company may face downside from slower revenue growth, heavy AI-related spending, and a $5 billion loss in 2025, while highlighting Rocket Lab as a smaller public alternative with a $49 billion market cap but elevated valuation at 74x sales. Overall, the piece is a comparative, cautionary take on space-sector exposure rather than a direct market-moving development.

Analysis

The market is being set up for a classic scarcity premium trade, but the better read is that the IPO hype creates a temporary flow event more than a durable fundamental rerating. A mega-cap listing with unusually broad retail allocation can pull in momentum capital first, then compress forward returns as the float expands and early lockup selling arrives. That creates a window where the “story” can outrun the underlying cash-generation reality, especially if investors anchor on the IPO scale rather than the slope of future growth.

The more interesting second-order effect is competitive positioning: if the private incumbent is distracted by adjacent bets and capital intensity, public rivals with narrower focus can gain relative credibility even without matching absolute scale. RocketLab benefits not because it is cheap in absolute terms, but because it is a cleaner expression of the space thesis with a clearer path to operating leverage if execution holds. The risk is that the market is already assigning it much of that future optionality, so any schedule slip on next-gen launch milestones likely triggers a sharp de-rating rather than a gradual slowdown.

The contrarian view is that the consensus may be overestimating how much retail enthusiasm can support an extremely large IPO while underestimating how quickly sentiment rotates once the trade becomes crowded. The best timing is likely post-listing, after the initial pop and before hard operational evidence either confirms or contradicts the growth narrative. Over a 3-6 month horizon, the setup favors relative-value expressions more than outright directional bets, because both names are still priced as if execution risk is lower than it really is.

Key Decisions for Investors

• Avoid chasing the IPO print in the first 1-2 weeks; wait for the first post-listing consolidation or lockup overhang before considering exposure. Best risk/reward is likely after the initial retail-driven spike fades.
• Favor a relative-value long RKLB / short new SpaceX exposure if feasible in the private market or via proxy basket; thesis is cleaner-space-pure-play versus conglomerate distraction, but keep size modest because RKLB is still priced for perfection.
• For public-market expression, consider a tactical long RKLB only on a 10-15% pullback to reduce multiple risk; target 20-30% upside if launch milestones are met, but cut quickly on any meaningful program delay.
• Use event-driven hedging into the IPO window: short a broad space/innovation basket against any long RKLB position to isolate company-specific execution. This reduces beta to retail sentiment and protects if the whole segment de-rates.
• If SpaceX becomes liquid, wait for the first earnings cycle rather than the IPO; the initial valuation likely embeds growth that will not be visible in the first 2-3 quarters, creating downside risk once narrative meets disclosure.